This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes. - Monotherapy - Combined therapy
Long-term treatment of patients aged 12 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) who have an amenable mutation.
inflammation and pain in following diseases: degenerative arthritis (osteoarthritis), periarthritis of shoulder, tendonitis·tenosynovitis, peritendinitis, humeral epicondylitis (tennis elbow), myalgia, and post-traumatic swelling and pain